KRAS and non-small cell lung carcinoma: Céline et al. [55] reported a significant worse survival (HR=1.35, 95% CI 1.16-1.56) of KRAS mutant NSCLC compared with KRAS wild-type NSCLC based on a meta-analysis of 28 studies early in 2004.